🏛️ Beacon Hill Sends Cannabis Commission Overhaul to Healey in Three Days Flat

Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.

Today's edition is sponsored by 1440 Media, and The Hybrid podcast. New episode coming out next week. Their support keeps these briefings free and focused on what actually matters.

Three days ago a conference committee in Massachusetts finalized a deal. Today that deal is on the governor's desk with an emergency preamble attached. In Providence, a federal judge just told Rhode Island its social equity architecture cannot survive the Dormant Commerce Clause. In Washington, Roger Stone is asking out loud who is blocking Donald Trump's own rescheduling order. Every story in today's edition is about somebody finally being forced to say what they already knew.

🏛️ Beacon Hill blinks
⚖️ Rhode Island's residency rule falls
💸 280E: $2.24 billion and counting

Massachusetts sent H 5350 to Governor Maura Healey this week at a tempo worth noticing. Conference committee deal on Monday. House 155-0 on Wednesday. Senate by voice vote on Thursday. Emergency preamble attached, meaning the bill takes effect the moment Healey signs. Monday's edition covered the substance: Cannabis Control Commission down from five members to three, all appointments to the governor, current commissioner terms terminated on signing, retail license cap doubled to six. The pace of this thing is what should raise eyebrows. The legislature is not known to move this fast on anything, and emergency preambles are not standard equipment for bills about license caps and commission seats. Beacon Hill is signaling that it wants new commissioners doing the work. The agency has plenty to do, including yet another legislative study to run, but the Legislature has decided the institutional reset cannot wait for the next budget cycle or the next news cycle. New people in the chairs, and soon. (State House News Service; Marijuana Moment)

🌿 The conference committee left one of the biggest fights on the table. The House had voted to ban unlicensed intoxicating hemp sales and build a new regulatory framework. The Senate wanted to study the issue. Conference went with the Senate, and the study now lands with the Cannabis Control Commission. All public indications before the federal November trigger were that Massachusetts was headed toward a permissive beverage framework. The Legislature looked at the calendar, looked at Section 781, and decided doing anything now was premature in light of the federal timeline and ongoing advocacy. As if the commission did not have enough to do between seating new members and running an agency, it can now also spend its time studying how to do more regulating. (Cannabis Business Times)

U.S. District Judge Melissa DuBose granted a preliminary injunction Wednesday halting Rhode Island's cannabis retail lottery, finding three out-of-state plaintiffs from Florida and California likely to succeed on Dormant Commerce Clause and Equal Protection grounds. Rhode Island had 97 applications in for roughly 20 licenses: 56 general retail, 19 worker cooperative, 23 social equity, with 31 clustered in Zone 6 alone. Applicants who paid fees, locked leases, and cleared municipal zoning are now stuck. DuBose's ruling guts both the state's longstanding residency requirement for license holders and the social equity framework that tied eligibility to specific Rhode Island census tracts. She was direct on the second point: letting someone qualify for a social equity license based only on where they lived, while excluding someone who actually suffered harm from cannabis enforcement but lived elsewhere, will not survive rational basis review. The state argued federal illegality meant there was no interstate commerce to protect. DuBose rejected it. Other states with residency requirements should be watching closely. Federal districts are working these questions case by case, and Rhode Island now joins the list ripe for circuit-level escalation. Residency as a regulatory tool is getting more nuanced by the month, and the clean version of social equity that tied repair to state borders is running out of constitutional runway. (Providence Business News; The Boston Globe)

Whitney Economics estimates licensed cannabis operators paid $2.24 billion in excess federal taxes in 2025 because IRS section 280E still blocks ordinary deductions for companies handling a Schedule I product. Beau Whitney is the industry's go-to hired gun for numbers, which is why the numbers travel. Effective tax rates approaching 70 percent explain why operators that look functional from the outside keep running out of cash underneath. Wave the number back at every prohibitionist campaign currently circulating. Arizona and Massachusetts both have active ballot efforts trying to repeal adult use, and the pitch in both places boils down to whether the industry is worth keeping. Repeal means the excess federal revenue goes with it. The Treasury quietly loses a line item it did not have to fight for. Of course, there is a cleaner version of this conversation where Washington finalizes rescheduling and lets legal operators take ordinary deductions like every other legal business, but the federal government is happy to stay on both sides of the contradiction. Licensed enough to tax, suspect enough to punish. Pigs at the trough. (Rutland Herald)

🎖️ The U.S. Army is moving to block a proposed cannabis dispensary near Fort Cavazos in Texas, arguing the business threatens troop readiness, discipline, and federal law compliance. Local officials already approved it. Army leadership is pressing to stop it anyway. Local approval near a military installation does not equal a clear path forward. (Task & Purpose)

Roger Stone spent the day asking publicly who inside the Trump administration is holding up marijuana rescheduling. Stone is a snake oil salesman and a creep, and that reputation is earned. He is also not wrong. Trump signed an executive order in December directing the Department of Justice to move cannabis from Schedule I to Schedule III in the most expeditious manner. Three months later, nothing has moved. The DEA says the appeal process remains pending. Pam Bondi was fired last week. Acting Attorney General Todd Blanche, previously Trump's personal lawyer, has reportedly been involved in drafting the final rule and is the person Trump reportedly wants to sign it before the Senate confirms a permanent replacement. Plenty of people inside this administration are in no hurry to reschedule, regardless of what the president himself ordered. Rescheduling was never going to be automatic. It still is not, and the longer Blanche sits with the rule unsigned, the more the inside-the-building math starts to look like the deciding factor. (Marijuana Moment)

Hemp Beverage Alliance president Christopher Lackner is using a friendly MJBizDaily profile to deliver an unfriendly message to Congress: the clock is running. Roughly $1.3 billion in annual beverage sales, around 328,000 jobs across the broader hemp economy, and a November trigger under Section 781 that would make products with more than 0.4 milligrams of THC per container illegal under federal law. Lackner is right, and the industry should be amplifying him, not hedging. This is deadline politics now, not posture politics. Either Congress buys time for a workable replacement framework or a blunt statutory cap lands on lawful categories that grew under the last federal compromise. Markets adapt to tough rules. They do not adapt to rules that arrive late and land like a trapdoor. (MJBizDaily)

📈 Tilray reported fiscal third-quarter cannabis revenue up 19 percent to $64.8 million, powered by a 73 percent jump in international sales and an 8 percent bump in Canada, while beverage revenue fell 24 percent to $42.6 million. Cabot Wealth is writing from an investor angle, but in a sector defined by price compression and weak consumer spending, finding growth through international cannabis distribution is a useful data point. CEO Irwin Simon is publicly betting the federal hemp crackdown gets rewritten into a regulated low-dose framework rather than allowed to kill the category. That is where sophisticated operators still think the puck is going. (Cabot Wealth Network)

Edibles.com opened a flagship store in Atlanta's Inman Park on April 9th with 21-and-over access, ID checks, concierge service, and a shelf that includes Cann, Wana, and Wyld. Take the "national standard" language as marketing, but take the bet seriously. Edibles.com is a reputable consumer brand putting a polished, adult-gated storefront in public view in a state where medical access remains narrow. The question is whether disciplined retail like this, plus Target and other mainstream players quietly expanding into hemp-derived beverages, is enough to normalize cannabinoids with the geriatrics in Congress before the November trigger. Time will tell, and the honest answer is probably no. Brands of this size will survive November either way. They will stock something else and keep the lights on. The supply chain behind them will not. Smaller manufacturers, extractors, co-packers, and distributors that built their businesses around the 2018 Farm Bill definition are getting cut at the knees. The storefronts will outlast the statute. The infrastructure behind them might not. (Cannabis Business Times)

🚔 A Justice Department-backed study at Virginia Commonwealth University used 3D-printed cartridges and colorimetric dyes to distinguish Delta-9 THC from CBD in breath samples, which researchers called a proof of concept for a portable roadside tool. The science is very early, and the road from proof of concept to evidence a jury will rely on is long. Breath-based impairment testing has to clear admissibility, chain of custody, scientific validation, and the kind of cross-examination that tends to dismantle novel forensic tools the first time they reach a courtroom. The politics will arrive long before the evidence does. (The Independent)

Opponents of Georgia Senate Bill 220 are trying to move the fight from the legislature to the governor's office. Georgians for Responsible Marijuana Policy says the bill authorizes vaping, broadens product forms and qualifying conditions, weakens informed-consent protections, and would allow possession of up to 12,000 milligrams of THC. Set the merits aside. The strange thing about American medical cannabis markets has always been who gets to decide what counts as medicine. Everywhere else in healthcare, that conversation happens between a provider and a patient about the right therapeutic approach, including how the medicine is delivered. In cannabis, it happens between lobbyists and a state legislature about whether you are allowed to vaporize, ingest, or inhale the thing your doctor already said you qualify for. Georgia is not unusual in this. Georgia is just the current example of how weird it looks when you say it out loud. Once a traditionally restrictive medical state starts loosening product type, potency, and access rules at the same time, the debate stops being about patient relief and starts being about program identity, which was always the wrong frame for a medicine. (Now Georgia)

🌿 A Harris Poll commissioned by seed company Royal Queen Seeds found 72 percent of cannabis consumers say they are very concerned about pesticides and 67 percent would choose cleaner, lower-potency cannabis over higher-THC product grown with pesticides. Sentiment data from a survey paid for by a home-grow company is not gospel, but the directional point tracks. Once consumers start caring about inputs and testing, the THC percentage on the jar stops carrying the whole sales pitch. (High Times)

Ohio regulators are defending SB 56 as a safety measure, with Division of Cannabis Control Superintendent Jim Canepa drawing a hard contrast between licensed marijuana tracked and tested in-state and intoxicating hemp products sold through gas stations and vape shops without state oversight. Accountability, testing, and traceability are real values, and the state is not wrong to prize them. The gap in the logic is economic. Canepa's alternative, buy your cannabis drinks through licensed Ohio dispensaries, assumes a product manufactured and distributed inside Ohio's regulated marijuana market is economically equivalent to one that travels through the hemp channel. It is not. Ohio's cannabis market must exist entirely within Ohio's borders. So must Kentucky's. So must Michigan's. The hemp market lets a small brand produce at scale in one state and distribute across the country. That scale is value. Value is margin. Margin is the difference between staying open and closing the doors. Ohio is not just deciding which channel sells beverages. It is deciding which economic model survives, and it is picking the one with the smaller addressable market. Defensible as policy. Should not be sold as simple consumer protection. (The Statehouse News Bureau)

🏰 A 19th-century Welsh mansion that once hosted a ball for King Charles has turned up as the site of a large cannabis grow, with North Wales Police saying roughly 12 rooms on the top floor were being used and arrests are expected. Lurid story, simple reminder. Illicit cultivation still finds cover in neglected real estate, stolen utilities, and properties nobody is watching closely enough. (The Independent)

A UCLA Health-led review published in JAMA in late 2025 examined more than 2,500 studies and concluded that evidence from randomized clinical trials does not support cannabis or cannabinoids for most conditions they are promoted for, including acute pain and insomnia. High-potency cannabis use was associated with meaningfully higher rates of psychotic symptoms and generalized anxiety disorder. Roughly 29 percent of medical cannabis users met criteria for cannabis use disorder. Take the critique seriously. High-potency products need controls, warnings, and real guardrails, particularly for novice and unfamiliar consumers. It is almost as if the cleanest policy answer would be to keep potent products behind the counter in age-gated, tested, regulated dispensaries while allowing low-dose, well-labeled products to reach a broader consumer base through traditional retail channels that already know how to manage age verification, inventory tracking, and quality control. Hmm. Where have we heard that one before. (JAMA; UCLA Health)

🔥 Texas is tightening enforcement around hemp-derived THC, and columnist Chris Tomlinson draws the familiar line: when legal pathways narrow, illicit supply fills the gap. State officials are trying to solve a real product-safety and youth-access problem, but the mechanism risks recreating the exact market conditions legalization was supposed to fix. (Houston Chronicle)